| Names | |
|---|---|
| Preferred IUPAC name
(5Z,8Z,11Z,14Z)-N-[(2R)-1-Hydroxypropan-2-yl]icosa-5,8,11,14-tetraenamide | |
| Other names
AM-356; Arachidonyl-1'-hydroxy-2'-propylamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider |
|
PubChem CID |
|
| UNII | |
| |
| |
| Properties | |
| C23H39NO2 | |
| Molar mass | 361.570 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Methanandamide (AM-356) is a synthetically created stable chiral analog of anandamide with improved metabolic stability.[1] Its effects have been observed to act on the cannabinoid receptors (specifically on CB1 receptors,[2] which are part of the central nervous system) found in different organisms such as mammals, fish, and certain invertebrates (e.g. Hydra).[3][4][5]
References
- Abadji V; Lin S; Taha G; Griffin G; Stevenson LA; Pertwee RG; Makriyannis A (1994). "(R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability". Journal of Medicinal Chemistry. 37 (12): 1889–93. doi:10.1021/jm00038a020. PMID 8021930.
- Childers SR. Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J. 2006 Mar 10;8(1):E112-7. doi:10.1208/aapsj080113 PMID 16584117
- Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci. 2005 Jun 8;25(23):5645-50. doi:10.1523/JNEUROSCI.0951-05.2005 PMID 15944392
- Alexander SPH. Methanandamide. In xPharm: The Comprehensive Pharmacology Reference. 2007; pp 1-3. ISBN 9780080552323 doi:10.1016/B978-008055232-3.62144-0
- Mock ED, Gagestein B, van der Stelt M. Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. Prog Lipid Res. 2023 Jan;89:101194. doi:10.1016/j.plipres.2022.101194 PMID 36150527
